This article outlines key clinical considerations for community pharmacists to optimize antidepressant medication reviews, directly supporting evidence-based prescribing and monitoring practices.

The Alzheimer's Association provides updated guidelines for detecting, monitoring, and mitigating amyloid-related imaging abnormalities (ARIA) in patients receiving anti-amyloid immunotherapies for Alzheimer's disease.

This national analysis indicates that state-level kratom bans correlate with significantly lower rates of severe medical outcomes and healthcare utilization compared to unrestricted states, informing regulatory strategies for substance use disorders.

This editorial highlights the urgent need for integrated treatment frameworks addressing stimulant use disorder and co-occurring psychiatric conditions like ADHD, while noting emerging pharmacotherapies such as a cocaine vaccine and gaps in current evidence-based interventions.

A common antidepressant demonstrates efficacy in reducing methamphetamine use, offering a potential pharmacological treatment option for substance use disorder.

The Lithuanian translation of the Liebowitz Social Anxiety Scale Self-Report demonstrates excellent internal consistency, though high correlations between subscales suggest limited utility for differentiating specific anxiety domains in cross-sectional research.

A pilot study indicates that 8-session group CBT significantly reduces hostile attribution bias and improves social functioning and quality of life in adolescents with ASD traits, though QOL gains may not linearly correlate with bias reduction.

Intensive Short-Term Dynamic Psychotherapy demonstrates large, durable efficacy for treatment-resistant depression, though the hypothesized mechanism of action involving sequential reduction of emotional repression was not supported by reanalysis data.

A pilot program demonstrates that Ketamine-Assisted Therapy (KAT) is feasible and effective for depression, anxiety, and PTSD in an Indigenous context when delivered through a culturally responsive model.

An executive order is accelerating the pace of clinical research into psychedelics for treating severe mental health conditions, potentially expediting future FDA approvals and prescribing pathways.

A Trump executive order aims to accelerate research and access to psychedelics for mental health conditions, potentially influencing the investment landscape for related biotechs.

A US executive order directs the FDA to accelerate review of psychedelic therapies including ibogaine for addiction, depression, and PTSD while mandating $50 million in federal funding to lower research barriers.

President Trump signed an executive order to boost federal research into psychedelics like psilocybin, LSD, and MDMA for potential mental health treatments.

Virginia establishes regulatory frameworks for potential psilocybin-assisted therapy, signaling a shift in state-level policy regarding this emerging psychopharmacological treatment.

This review proposes a framework linking neuroinflammation and immune dysregulation to computational deficits in schizophrenia, advocating for multi-modal biomarkers to enable precision medicine rather than offering specific new drug prescribing guidance.

This systematic review identifies pretreatment subcallosal cingulate functional connectivity patterns as potential biomarkers for predicting response to brain stimulation therapies (DBS, rTMS, ECT, TUS) in treatment-resistant depression.

This review details how cerebral iron dyshomeostasis contributes to the pathophysiology of neuropsychiatric disorders like depression, schizophrenia, and ADHD, identifying iron metabolism as a potential therapeutic target.

A head-to-head trial indicates that baseline connectivity to the TMS target site predicts anxiety improvement in depression patients, whereas induced connectivity changes did not predict outcomes, suggesting circuit architecture is a critical factor for targeting protocols.

This article provides clinical guidance on managing antidepressant side effects, helping prescribers decide when to continue therapy versus switching medications.

This article provides clinical prescribing guidance for the novel muscarinic antagonist combination xanomeline/trospium, a new treatment option for schizophrenia.

This podcast discusses the emerging potential of GLP-1 agonists to treat psychiatric conditions and mitigate metabolic side effects of antipsychotics like clozapine, challenging traditional monoamine-based treatment paradigms.

A clinical trial is recruiting to evaluate transcranial photobiomodulation as an intervention for somatic symptoms in treatment-resistant depression.

Preclinical PET imaging demonstrates that subanesthetic ketamine rapidly increases cAMP activity via PDE4 inhibition in rodents and non-human primates, providing mechanistic evidence for its rapid antidepressant effects.

A study identifying a specific serotonin circuit linking SSRIs to tinnitus provides a mechanistic explanation for this adverse effect and suggests a potential therapeutic target.

This systematic review elucidates the mechanism by which dopaminergic modulation of pancreatic beta-cells contributes to antipsychotic-induced glucose dysregulation, offering critical mechanistic insight for managing metabolic side effects in patients treated with antipsychotics.

This article identifies mTOR-driven autophagy-inflammation crosstalk as a core mechanism in schizophrenia pathophysiology, suggesting potential targets for future pharmacological intervention.